| |
ICS cohorts |
| |
QD cohort (n=941) |
BD cohort (n=25,893) |
| Characteristic |
Baseline year |
Year after step-down |
p value |
Baseline year |
Year after step-down |
p value |
| No consultation for LRTI, n (%) |
803 (85.3) |
845 (89.8) |
0.002‡ |
21,409 (82.7) |
22,709 (87.7) |
<0.001‡ |
| Daily ICS dose (μg/d), median (IQR) |
164 (99-329) |
219 (137-384) |
<0.001* |
219 (110-384) |
274 (164-493) |
<0.001* |
| ICS adherence ≥70%, n (%) |
440 (46.8) |
710 (75.5) |
<0.001† |
13,495 (52.1) |
16,184 (62.5) |
<0.001† |
| Spacer device used, n (%) |
106 (11.3) |
71 (7.5) |
0.003‡ |
4630 (17.9) |
3221 (12.4) |
<0.001‡ |
| Daily SABA dose (μg/d), median (IQR) |
110 (55-274) |
164 (55-329) |
<0.001* |
164 (55-329) |
219 (110-438) |
<0.001* |
| Controller: total asthma med ratio, mean (SD) |
0.58 (0.25) |
0.60 (0.20) |
<0.001* |
0.54 (0.24) |
0.60 (0.20) |
<0.001* |
| |
ICS/LABA cohorts |
| |
QD cohort (n=505) |
BD cohort (n=20,309) |
| No consultation for LRTI, n (%) |
406 (80.4) |
419 (83.0) |
0.287‡ |
15,939 (78.5) |
16,796 (82.7) |
<0.001‡ |
| Daily ICS dose (μg/d), median (IQR) |
329 (164-756) |
362 (210-712) |
0.280* |
395 (164-822) |
460 (247-855) |
<0.001* |
| ICS adherence ≥ 70%, n (%) |
297 (58.8) |
399 (79.0) |
<0.001† |
13,019 (64.1) |
13,731 (67.6) |
<0.001† |
| Spacer device used, n (%) |
70 (13.9) |
69 (13.7) |
1.0‡ |
3975 (19.6) |
2799 (13.8) |
<0.001‡ |
| Daily SABA dose (μg/d), median (IQR) |
186 (55-384) |
219 (110-438) |
0.086* |
219 (110-548) |
219 (110-548) |
0.001* |
| Controller: total asthma med ratio, mean (SD) |
0.60 (0.26) |
0.60 (0.20) |
0.002* |
0.54 (0.27) |
0.60 (0.20) |
<0.001* |
*Wilcoxon signed rank test; †marginal homogeneity test; ‡McNemar test
BD: Twice Daily; IQR: Interquartile Range; LABA: Long-Acting β-Agonist; LRTI: Lower Respiratory Tract Infection; QD: Once Daily; SABA: Short-Acting β-Agonist |
